|
US1019519A
(en)
|
1911-07-11 |
1912-03-05 |
Oscar Martin Polin |
Apparatus for making backing for teeth.
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
ATE391492T1
(de)
|
1997-07-29 |
2008-04-15 |
Alcon Lab Inc |
Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
|
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US6451828B1
(en)
|
2000-08-10 |
2002-09-17 |
Elan Pharmaceuticals, Inc. |
Selective inhibition of glutaminase by bis-thiadiazoles
|
|
AU2002305926A1
(en)
|
2001-02-05 |
2002-10-08 |
Exegenics Inc. |
Cysteine protease inhibitors
|
|
CA2520172C
(en)
*
|
2003-03-27 |
2012-10-02 |
Lankenau Institute For Medical Research |
Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
DE602004023516D1
(de)
|
2003-08-07 |
2009-11-19 |
Allergan Inc |
Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
ES2367311T3
(es)
|
2004-04-15 |
2011-11-02 |
University Of Florida Research Foundation, Inc. |
Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
|
|
US7928140B2
(en)
|
2007-08-02 |
2011-04-19 |
Amgen Inc. |
Benzothiazole PI3 kinase modulators for cancer treatment
|
|
CN101932325B
(zh)
*
|
2007-11-30 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
|
WO2009104696A1
(ja)
|
2008-02-19 |
2009-08-27 |
株式会社アーネストメディスン |
身体機能の回復に有用な経口又は経腸組成物
|
|
TR201910726T4
(tr)
*
|
2009-01-26 |
2019-08-21 |
Astrazeneca Uk Ltd |
Arginaz inhibitörleri ve kullanım yöntemleri.
|
|
US20130109643A1
(en)
|
2010-05-10 |
2013-05-02 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
WO2012006506A1
(en)
|
2010-07-09 |
2012-01-12 |
Massachusetts Institute Of Technology |
Metabolic gene, enzyme, and flux targets for cancer therapy
|
|
AU2011329619A1
(en)
|
2010-11-18 |
2013-05-02 |
Deuteria Pharmaceuticals, Inc. |
3-deutero-pomalidomide
|
|
CN103402549A
(zh)
*
|
2010-12-31 |
2013-11-20 |
考瑞多制药公司 |
精氨酸酶抑制剂及其使用方法
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
|
CN103030597B
(zh)
|
2011-09-30 |
2014-10-01 |
南昌滨西科技有限公司 |
肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
|
|
AU2012326109A1
(en)
*
|
2011-10-19 |
2014-05-29 |
Mars, Incorporated |
Inhibitors of arginase and their therapeutic applications
|
|
EA026656B1
(ru)
*
|
2011-11-21 |
2017-05-31 |
Калитера Байосайенсиз Инк. |
Гетероциклические ингибиторы глютаминазы
|
|
US8604016B2
(en)
|
2011-11-21 |
2013-12-10 |
Calithera Biosciences Inc. |
Heterocyclic inhibitors of glutaminase
|
|
AU2013266243A1
(en)
|
2012-05-24 |
2014-12-18 |
Beth Israel Deaconess Medical Center, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
|
|
US9694015B2
(en)
|
2012-09-10 |
2017-07-04 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
|
US9618514B2
(en)
|
2012-09-17 |
2017-04-11 |
Agios Pharmaceuticals, Inc |
Methods of evaluating patients using E-cadherin and vimentin
|
|
LT2920168T
(lt)
|
2012-11-16 |
2021-10-25 |
Calithera Biosciences, Inc. |
Heterociklinis gliutaminazės inhibitorius
|
|
KR20150085078A
(ko)
|
2012-11-21 |
2015-07-22 |
아지오스 파마슈티컬스 아이엔씨. |
글루타마제 억제제 및 사용 방법
|
|
WO2014079011A1
(en)
|
2012-11-22 |
2014-05-30 |
Agios Pharmaceuticals, Inc. |
Heterocyclic compounds for inhibiting glutaminase and their methods of use
|
|
KR20150091389A
(ko)
*
|
2012-12-03 |
2015-08-10 |
칼리테라 바이오사이언시즈 인코포레이티드 |
글루타미나제의 헤테로사이클릭 억제제에 의한 암 치료
|
|
CN105324362B
(zh)
*
|
2013-03-15 |
2017-05-24 |
百时美施贵宝公司 |
Ido抑制剂
|
|
WO2015061432A1
(en)
|
2013-10-25 |
2015-04-30 |
Calithera Biosciences, Inc. |
Treatment of viral infections with inhibitors of glutaminase
|
|
TWI617309B
(zh)
*
|
2013-10-25 |
2018-03-11 |
製藥公司 |
使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
|
|
GB201322725D0
(en)
*
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
US20170165364A1
(en)
*
|
2014-02-21 |
2017-06-15 |
Idac Theranostics, Inc. |
Therapeutic agent for solid cancer
|
|
US20150258082A1
(en)
|
2014-03-14 |
2015-09-17 |
Francesco Parlati |
Combination therapy with glutaminase inhibitors
|
|
US10221459B2
(en)
|
2014-05-13 |
2019-03-05 |
Case Western Reserve University |
Compositions and methods of treating cancer harboring PIKC3A mutations
|
|
EP3154590B1
(en)
|
2014-06-13 |
2021-04-14 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
|
WO2016004413A2
(en)
|
2014-07-03 |
2016-01-07 |
Board Of Regents, University Of Texas System |
Gls1 inhibitors for treating disease
|
|
WO2016004418A1
(en)
|
2014-07-03 |
2016-01-07 |
Board Of Regents, University Of Texas System |
Glutaminase inhibitor therapy
|
|
WO2016014890A1
(en)
|
2014-07-24 |
2016-01-28 |
Calithera Biosciences, Inc. |
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
|
EA037738B1
(ru)
|
2014-08-07 |
2021-05-17 |
Калитера Байосайенсиз, Инк. |
Кристаллические формы ингибиторов глутаминазы
|
|
WO2016054388A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Glutaminase inhibitors
|
|
WO2016077632A2
(en)
|
2014-11-13 |
2016-05-19 |
Buck Institute For Research On Aging |
Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
|
|
EA037152B1
(ru)
*
|
2015-03-30 |
2021-02-11 |
Калитера Байосайенсиз, Инк. |
Способ лечения рака
|
|
EP3280415A4
(en)
|
2015-04-06 |
2018-12-26 |
Calithera Biosciences Inc. |
Treatment of lung cancer with inhibitors of glutaminase
|
|
CA2994165A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using glutamine analogues, including don
|
|
EP3355875B1
(en)
|
2015-10-01 |
2021-09-29 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
CA3000996A1
(en)
|
2015-10-05 |
2017-04-13 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
|
IL292302B2
(en)
|
2016-05-20 |
2023-10-01 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating factors in cancer immunotherapy
|
|
WO2018039441A1
(en)
|
2016-08-25 |
2018-03-01 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
|
WO2018039442A1
(en)
|
2016-08-25 |
2018-03-01 |
Calithera Biosciences, Inc. |
Treatment of cancer with inhibitors of glutaminase
|
|
MX2019002108A
(es)
|
2016-08-25 |
2019-07-08 |
Calithera Biosciences Inc |
Terapia de combinacion con inhibidores de glutaminasa.
|
|
CN110730664A
(zh)
|
2017-03-10 |
2020-01-24 |
卡利泰拉生物科技公司 |
含谷氨酰胺酶抑制剂的组合疗法
|
|
US20210177841A1
(en)
*
|
2017-11-03 |
2021-06-17 |
Calithera Biosciences, Inc. |
Conjoint therapy with glutaminase inhibitors
|